{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:14:21Z","timestamp":1768414461204,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68526-0","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T20:03:33Z","timestamp":1722369813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Computational study of novel natural agonists targeting farnesoid X receptor"],"prefix":"10.1038","volume":"14","author":[{"given":"Xindan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junliang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"3","key":"68526_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon, G., Baranova, A. & Younossi, Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34(3), 274\u2013285 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"22","key":"68526_CR2","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella, M. E. Nonalcoholic fatty liver disease: A systematic review. Jama 313(22), 2263\u20132273 (2015).","journal-title":"Jama"},{"issue":"1","key":"68526_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md) 67(1), 328\u2013357 (2018).","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"68526_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N.Engl. J. Med. 390(6), 497\u2013509 (2024).","journal-title":"N.Engl. J. Med."},{"issue":"11","key":"68526_CR5","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 29(11), 2919\u20132928 (2023).","journal-title":"Nat. Med."},{"issue":"2","key":"68526_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a\/b trial. Nat. Med. 29(2), 392\u2013400 (2023).","journal-title":"Nat. Med."},{"issue":"2","key":"68526_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","volume":"5","author":"L Ding","year":"2015","unstructured":"Ding, L. et al. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharmaceut. Sin. B 5(2), 135\u2013144 (2015).","journal-title":"Acta Pharmaceut. Sin. B"},{"key":"68526_CR8","doi-asserted-by":"publisher","first-page":"109609","DOI":"10.1016\/j.biopha.2019.109609","volume":"121","author":"Y Xi","year":"2020","unstructured":"Xi, Y. & Li, H. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. Biomed. Pharmacother. Biomed. Pharmacother. 121, 109609 (2020).","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"issue":"6","key":"68526_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","volume":"29","author":"S Fiorucci","year":"2020","unstructured":"Fiorucci, S. et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opinion Investig. Drugs 29(6), 623\u2013632 (2020).","journal-title":"Expert Opinion Investig. Drugs"},{"issue":"4","key":"68526_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1517\/14728221003652463","volume":"14","author":"MK Kim","year":"2010","unstructured":"Kim, M. K. et al. Targeting orphan nuclear receptor SHP in the treatment of metabolic diseases. Expert Opinion Therap. Targets 14(4), 453\u2013466 (2010).","journal-title":"Expert Opinion Therap. Targets"},{"issue":"439","key":"68526_CR11","doi-asserted-by":"publisher","first-page":"ra78","DOI":"10.1126\/scisignal.aaf4850","volume":"9","author":"JH Lee","year":"2016","unstructured":"Lee, J. H. et al. Small heterodimer partner SHP mediates liver X receptor (LXR)-dependent suppression of inflammatory signaling by promoting LXR SUMOylation specifically in astrocytes. Sci. Signal. 9(439), ra78 (2016).","journal-title":"Sci. Signal."},{"issue":"2","key":"68526_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1053\/j.gastro.2010.03.033","volume":"139","author":"JH Lee","year":"2010","unstructured":"Lee, J. H. et al. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 139(2), 653\u2013663 (2010).","journal-title":"Gastroenterology"},{"issue":"3","key":"68526_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1042\/BJ20071637","volume":"413","author":"YS Lee","year":"2008","unstructured":"Lee, Y. S. et al. Orphan nuclear receptor SHP interacts with and represses hepatocyte nuclear factor-6 (HNF-6) transactivation. Biochem. J. 413(3), 559\u2013569 (2008).","journal-title":"Biochem. J."},{"issue":"3","key":"68526_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.29371","volume":"67","author":"MD Thompson","year":"2018","unstructured":"Thompson, M. D. et al. \u03b2-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis. Hepatology (Baltimore, Md) 67(3), 955\u2013971 (2018).","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"24","key":"68526_CR15","doi-asserted-by":"publisher","first-page":"17545","DOI":"10.1021\/acs.jmedchem.1c01017","volume":"64","author":"Y Fang","year":"2021","unstructured":"Fang, Y. et al. Recent advances in the medicinal chemistry of farnesoid X receptor. J. Med. Chem. 64(24), 17545\u201317571 (2021).","journal-title":"J. Med. Chem."},{"issue":"8","key":"68526_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.21037\/atm-20-4354","volume":"9","author":"F Tacke","year":"2021","unstructured":"Tacke, F. & Weiskirchen, R. Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann. Transl. Med. 9(8), 729 (2021).","journal-title":"Ann. Transl. Med."},{"key":"68526_CR17","doi-asserted-by":"publisher","first-page":"101152","DOI":"10.1016\/j.molmet.2020.101152","volume":"46","author":"S Talukdar","year":"2021","unstructured":"Talukdar, S. & Kharitonenkov, A. FGF19 and FGF21: NASH we trust. Mol. Metab. 46, 101152 (2021).","journal-title":"Mol. Metab."},{"issue":"1","key":"68526_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","volume":"72","author":"K Patel","year":"2020","unstructured":"Patel, K. et al. Cilofexor, a nonsteroidal fxr agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial. Hepatology (Baltimore, Md) 72(1), 58\u201371 (2020).","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"68526_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","volume":"78","author":"V Ratziu","year":"2023","unstructured":"Ratziu, V. et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J. Hepatol. 78(3), 479\u2013492 (2023).","journal-title":"J. Hepatol."},{"issue":"1","key":"68526_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","volume":"75","author":"SA Harrison","year":"2021","unstructured":"Harrison, S. A. et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J. Hepatol. 75(1), 25\u201333 (2021).","journal-title":"J. Hepatol."},{"key":"68526_CR21","doi-asserted-by":"publisher","first-page":"e005","DOI":"10.1621\/nrs.08005","volume":"8","author":"S Modica","year":"2010","unstructured":"Modica, S., Gadaleta, R. M. & Moschetta, A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal. 8, e005 (2010).","journal-title":"Nucl. Recept. Signal."},{"issue":"1","key":"68526_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/hep.29724","volume":"68","author":"ZM Younossi","year":"2018","unstructured":"Younossi, Z. M. et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatol. (Baltimore, Md) 68(1), 361\u2013371 (2018).","journal-title":"Hepatol. (Baltimore, Md)"},{"issue":"47","key":"68526_CR23","doi-asserted-by":"publisher","first-page":"18180","DOI":"10.1074\/jbc.RA118.004652","volume":"293","author":"N Wang","year":"2018","unstructured":"Wang, N. et al. Ligand binding and heterodimerization with retinoid X receptor \u03b1 (RXR\u03b1) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding. J. Biol. Chem. 293(47), 18180\u201318191 (2018).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"68526_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/hep.22661","volume":"49","author":"MO Hoeke","year":"2009","unstructured":"Hoeke, M. O. et al. Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters. Hepatology (Baltimore, Md) 49(1), 151\u2013159 (2009).","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10215","key":"68526_CR25","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England) 394(10215), 2184\u20132196 (2019).","journal-title":"Lancet (London, England)"},{"issue":"1","key":"68526_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","volume":"20","author":"U Beuers","year":"2023","unstructured":"Beuers, U., Wolters, F. & Oude Elferink, R. P. J. Mechanisms of pruritus in cholestasis: Understanding and treating the itch. Nat. Rev. Gastroenterol. Hepatol. 20(1), 26\u201336 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"11","key":"68526_CR27","first-page":"2082","volume":"39","author":"PJ Pockros","year":"2019","unstructured":"Pockros, P. J. et al. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. Off. J. Int. Assoc. Study Liver 39(11), 2082\u20132093 (2019).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68526-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T20:04:41Z","timestamp":1722369881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68526-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68526"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68526-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17597"}}